Hsin-An Hou

Hematology — National Taiwan University Hospital, Taiwan

LeadR Profile

1 382 ScienceLeadR Reputation 1382
Network Map

Hematology

Subspecialties: Oncology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026

Source: PubMed

National Taiwan University Hospital

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 303

Citations

Citations: 6 823 1st author: 31 Last author: 23 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Divergent Clonal Trajectories of FLT3-ITD in Acute Myeloid Leukemia and Their Clinical and Transcriptomic Associations.
hematology, leukemia, leukemia, myeloid, acute, clonal evolution, leukemia, myeloid, diagnosis, mutation
Hematol Oncol20260
Clinicomolecular features and clonal evolution of KMT2A-PTD AML: prognostic impact of concurrent FLT3-ITD under 2022 ELN risk stratification.
clonal evolution
Blood Cancer J20260
Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis.
cytokines, fibrosis, phenotype, mutation, primary myelofibrosis, cytopenia
Ther Adv Hematol20260
Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
janus kinases, janus kinase inhibitors, medical oncology, primary myelofibrosis
J Clin Oncol Top journal20260
Response to "Comment on 'Consensus of the hematology society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)'".
hematology, hemoglobinuria
J Formos Med Assoc20260

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 5
N/A 4
Phase 2 3
Phase 1 2
Phase 2/Phase 3 1

By status:

Completed 5
Recruiting 5
Active not recruiting 2
Not yet recruiting 1
Terminated 1
Unknown 1

By type:

Interventional 11
Observational 4

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161 — injections, safety, anemia, pharmaceutical preparations, drug therapy, therapeutics, primary myelofibrosis
Phase 3Recruiting2026
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor na ve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806 — safety, tablets, symptom assessment, janus kinase inhibitors, spleen, primary myelofibrosis, thrombocytopenia
Phase 2Recruiting2024
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa 2b in Adult COVID 19 Patients With Comorbidities
NCT05808322 — comorbidity, sars-cov-2, safety, dexamethasone, covid-19, centers for disease control and prevention, u.s., severe acute respiratory syndrome-related coronavirus, antiviral agents, infections
Phase 2/Phase 3Not yet recruiting2023
Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low Intermediate 1 Risk Myelofibrosis
NCT05731245 — safety, syringes, primary myelofibrosis
Phase 2Recruiting2023
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
NCT05659732 — cells, pharmaceutical preparations, lymphoma, neoplasms, checkpoint kinase 1, leukemia, leukemia, myeloid, acute, capsules, leukemia, myeloid, gelatin, lymphoma, mantle-cell, therapeutics
Phase 1Recruiting2023

LeadR Networks

Main global connection map